(Q37563962)

21 August 2017

1 reference

title

Antidiabetic agents and cardiovascular risk in type 2 diabetes (English)

1 reference

21 August 2017

0 references

1 reference

Stuart W Zarich

1

1 reference

21 August 2017

language of work or name

1 reference

28 July 2009

1 reference

Nature Reviews Endocrinology

21 August 2017

published in

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

500-506

1 reference

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

The UGDP controversy: thirty-four years of contentious ambiguity laid to rest.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

PROactive: time for a critical appraisal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Glucose control and vascular complications in veterans with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Effects of intensive glucose lowering in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

A randomized trial of therapies for type 2 diabetes and coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Insulin infusion in acute illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

10-year follow-up of intensive glucose control in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Effect of a multifactorial intervention on mortality in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.150

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2009.150

1 reference

21 August 2017

1 reference